Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.
Multiple myeloma patients in the iMMagine-1 study were less heavily pretreated than in the CARTITUDE-1 trial of Carvykti, but Gilead noted that more patients receiving anito-cel had high-risk features.
Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.
The Phase III PATINA trial showed Ibrance added to typical HER2+ breast cancer therapy extended progression-free survival by 15 months.
The French group says it can only fund operations in the first quarter of 2025 but having secured “a clear and reasonable pathway towards an accelerated approval” after talks with the US Food and Drug Administration for its Viaskin Peanut patch in toddlers, the future is looking much brighter.
Roche is highlighting the fixed-duration dosing benefits of Lunsumio and Columvi over AbbVie/Genmab’s Epkinly in B-cell lymphomas as they fight for market dominance. However, the speed at which the companies complete Phase III studies could also be a deciding factor.
A Phase III trial testing the oral SERD showed a PFS benefit in ER+/HER2- advanced breast cancer in combination with a CDK4/6 inhibitor regardless of mutation status.
In identifying 10 drugs whose price increases added the most to US health care spending in 2023, ICER found Keytruda’s was backed by six studies. Gilead’s Biktarvy led the list of drugs whose increases lacked support.
The French group says it can only fund operations in the first quarter of 2025 but having secured “a clear and reasonable pathway towards an accelerated approval” after talks with the US Food and Drug Administration for its Viaskin Peanut patch in toddlers, the future is looking much brighter.
Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.
Founder Ken Mulvany has returned to the artificial intelligence drug discovery specialist determined to ensure it plays to its “foundational strengths.” The UK firm has therefore initiated a major restructuring plan, along with the intention to delist from Euronext Amsterdam.
The US election result brought stock market volatility especially to pharma and biotech companies but the poster children for approved GLP-1 agonists and vaccines were initially the hardest hit.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Plus deals involving Mitsubishi Tanabe/Dewpoint, Lilly/Rondo, Ono/Congruence, Bristol Myers Squibb/AI Proteins and more.
Private Company Edition: Atlas Venture closed its $450m Fund XIV after some notable exits. Also, Nuvig’s $161m series B round more than triples its $47m series A from 2022, while Maze’s $115m series D fell below its prior $190m round and Antag raised an €80m ($84.7m) series A.
